FDA Authorizes Aletta Robotic Blood Draw Device
Analysis based on 24 articles · First reported Aug 19, 2026 · Last updated Aug 27, 2026
The FDA authorization of the Aletta robotic blood draw device is expected to boost Vitestro's market position and accelerate adoption of automation in phlebotomy, potentially reducing labor costs and addressing staffing shortages. This could positively impact the medical device and healthcare technology sectors, while posing a competitive challenge to traditional phlebotomy service providers.
The U.S. United States — Food and Drug Administration (FDA) authorized the Aletta, the first standalone robotic device that can autonomously draw blood from a patient's arm. The device, made by Dutch medical robotics company Vitestro, uses near-infrared light and Doppler ultrasound to locate veins and then performs all steps of the blood draw, including applying a tourniquet, cleaning the skin, inserting and disposing of the needle, changing collection tubes, and applying a bandage. It is authorized for use in adult outpatients under the oversight of a trained phlebotomist, who can supervise up to three Aletta devices simultaneously. The FDA's decision was based on clinical data showing the device achieves successful blood draw rates comparable to or better than human phlebotomists, across a broad range of patients including those with difficult vein access and varying skin tones. The authorization aims to address a growing shortage of trained phlebotomists in the United States. The device received the CE mark in Europe and is already in use there. The FDA granted the authorization through its De Novo pathway for low-to-moderate risk novel devices.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard